FacebookTwitterRedditEmail

It’s the Cymbalta Stupid

Many are outraged that Eli Lilly gave nonprofits $3.9 million in grants last year for medical courses to “educate” doctors about the pain-and-fatigue ailment fibromyalgia–more than it spent for diabetes and Alzheimer’s which people already know they have.

But finding new diseases to justify a drug’s existence is the normal way pharma operates.

Especially Lilly who agreed to pay $1.42 billion for illegal marketing of its anti-psychotic Zyprexa last month–$615 million for criminally promoting it for dementia–another $62 million to 32 states for illegal pediatric marketing and agreed to resolve Medicaid fraud investigations into “rebates” at the same time. (And how was your year?)

And whose diabetes treatment Byetta is tanking since reports last summer of six deaths, at least two from pancreatitis.

But Lilly’s fibromyalgia-fighting drug, Cymbalta (duloxetine)–its second best seller after Zyprexa–is anything but normal.

Starting with the death of 19-year-old Cymbalta test subject Traci Johnson in 2004–who hanged herself in the Lilly Clinic in Indianapolis and had no history of mental problems–it has been beset by reports of baffling, rapid, unprovoked, and out of character suicides and suicide attempts.

A 37-year-old man described in the Feb. 2008 Journal of Clinical Psychopharmacology with a stable marriage and employment and no history of mental problems tried to kill himself with carbon monoxide two months after taking Cymbalta for back pain. “The patient was unable to state exactly why he wanted to commit suicide,” write the four physician authors all with the Department of Psychiatry and Behavioral Sciences at the University of Kansas Medical Center who note he returned to normal when the drug was stopped.

A 63-year-old man with no history of suicide attempts or ideation was similarly “unable to explain why he was having thoughts of wanting to die,” say the authors after becoming suicidal two weeks after being put on Cymbalta for fatigue, insomnia and sadness.

Last January, a Texas man prescribed Cymbalta for peripheral neuropathy because of a job that required him to be on his feet all day with no history mental problems “had a normal day at work, drove home, said he was going to grab a sandwich to his wife, and went and shot himself,” his family wrote a reporter.

In Feb. 2007, a 19-year-old Wisconsin college student recently put on Cymbalta “checked out books for a paper he was to write over the weekend,” emailed his resume “to see if he could get a spot on Obama’s team for the summer” and “then hung himself from his loft bed in his dorm,” writes his family. One month earlier, a 21-year old Midwest college student, recently put on Cymbalta, took his own life three minutes after speaking to his family while driving home and sounding fine, the family wrote a reporter.

Nor are incomprehensible and abrupt suicide attempts on Cymbalta a US phenomenon.

Doctors Bilal Salem and Elie Karam of the Saint George Hospital University Medical Center in Beirut, Lebanon write of similar “suicidality in apparently nonsuicidal patients after starting or increasing Duloxetine,” in the June 2008 Clinical Practice and Epidemiology in Mental Health.

Approved as an antidepressant and for diabetic nerve pain in 2004–soon after the Johnson suicide thanks to an unfazed FDA–Cymbalta soon proved to be the “Swiss Army Knife” of Lilly drugs says its hometown paper the Indianapolis Star–approved for general anxiety disorder and maintenance treatment of depression in 2007, for fibromyalgia in 2008 and with approvals for chronic knee and low back pain expected shortly.

In Europe it is in use for stress urinary incontinence but in the US its side effect of urinary retention landed Cymbalta on the FDA’s first Potential Signals of Serious Risks danger list in 2008. (FDA won’t release suicidal rates from stress urinary incontinence trials says reporter Jeanne Lenzer on Slate, who estimates them as 400 per 100,000 person-years for middle aged women.)

But some, like Shannon Brownlee, author of “Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer,” question the revenue-driven prescribothan. Should drugs “that may have a really serious side effect called suicide,” be used for simple knee or back pain, she asks in the Star.

No kidding! Cymbalta is also being studied for binge eating, social phobia, chronic fatigue, restless legs disorder, seasonal affective disorder, migraines, attention deficit disorder and childhood depression–despite known pediatric risks–PMS, menopause, alcoholism, panic disorder, obsessive compulsive disorder, kleptomania and the important medical condition: tennis elbow.

At the American Academy of Pain Medicine Annual Meeting in January, Lilly presented a study by its own doctors finding Cymbalta was superior to placebo in knee pain–in keeping with its penchant to publish studies by Lilly funded and Lilly employed doctors saying Cymbalta is safe.

Cymbalta is also a good use of state and third party payer dollars say Lilly funded doctors in “Differences In Medication Adherence and Healthcare Resource Utilization Patterns: Older Versus Newer Antidepressant Agents In Patients With Depression And/Or Anxiety Disorders” in the 2008-22 CNS Drugs who are fighting the “restrictive reimbursement policies for newer antidepressants,” in which pharmacy benefits managers are saying you want us to spend WHAT?

Getting benefits managers to cover the $200 a month cost for Cymbalta prescriptions for fibromyaglia may also be tough since the ailment has no clear cause, blood test or cure. Maybe Lilly will offer pointers in the medical courses it is funding.

MARTHA ROSENBERG is a columnist/cartoonist who writes about public health. She can be reached at: mrosenberg@evmark.org

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
Weekend Edition
July 19, 2019
Friday - Sunday
Rob Urie
The Blob Fought the Squad, and the Squad Won
Miguel A. Cruz-Díaz
It Was Never Just About the Chat: Ruminations on a Puerto Rican Revolution.
Anthony DiMaggio
System Capture 2020: The Role of the Upper-Class in Shaping Democratic Primary Politics
Andrew Levine
South Carolina Speaks for Whom?
Jeffrey St. Clair
Roaming Charges: Big Man, Pig Man
Bruce E. Levine
The Groundbreaking Public Health Study That Should Change U.S. Society—But Won’t
Evaggelos Vallianatos
How the Trump Administration is Eviscerating the Federal Government
Pete Dolack
All Seemed Possible When the Sandinistas Took Power 40 years Ago
Ramzy Baroud
Who Killed Oscar and Valeria: The Inconvenient History of the Refugee Crisis
Ron Jacobs
Dancing with Dr. Benway
Joseph Natoli
Gaming the Climate
Marshall Auerback
The Numbers are In, and Trump’s Tax Cuts are a Bust
Louisa Willcox
Wild Thoughts About the Wild Gallatin
Kenn Orphan
Stranger Things, Stranger Times
Mike Garrity
Environmentalists and Wilderness are Not the Timber Industry’s Big Problem
Helen Yaffe
Cuban Workers Celebrate Salary Rise From New Economic Measures
Brian Cloughley
What You Don’t Want to be in Trump’s America
David Underhill
The Inequality of Equal Pay
David Macaray
Adventures in Script-Writing
David Rosen
Say Goodbye to MAD, But Remember the Fight for Free Expression
Nick Pemberton
This Is Heaven!: A Journey to the Pearly Gates with Chuck Mertz
Dan Bacher
Chevron’s Oil Spill Endangers Kern County
J.P. Linstroth
A Racist President and Racial Trauma
Binoy Kampmark
Spying on Julian Assange
Rose Ramirez – Dedrick Asante-Mohammad
A Trump Plan to Throw 50,000 Kids Out of Their Schools
David Bravo
Precinct or Neighborhood? How Barcelona Keeps Rolling Out the Red Carpet for Global Capital
Ralph Nader
Will Any Disgusted Republicans Challenge Trump in the Primaries?
Dave Lindorff
The BS about Medicare-for-All Has to Stop!
Arnold August
Why the Canadian Government is Bullying Venezuela
Tom Clifford
China and the Swine Flu Outbreak
Missy Comley Beattie
Highest Anxiety
Jill Richardson
Weapons of the Weak
Peter Certo
Washington vs. The Squad
Peter Bolton
Trump’s Own Background Reveals the True Motivation Behind Racist Tweets: Pure White Supremacy
Colin Todhunter
From Mad Cow Disease to Agrochemicals: Time to Put Public Need Ahead of Private Greed
Nozomi Hayase
In Crisis of Democracy, We All Must Become Julian Assange
Wim Laven
The Immoral Silence to the Destructive Xenophobia of “Just Leave”
Cecily Myart-Cruz
McDonald’s: Stop Exploiting Our Schools
Kollibri terre Sonnenblume
Our Veggie Gardens Won’t Feed us in a Real Crisis
CounterPunch News Service
A Homeless Rebellion – Mission Statement/Press Release
Louis Proyect
Parallel Lives: Cheney and Ailes
David Yearsley
Big in the Bungalow of Believers
Ellen Taylor
The Northern Spotted Owls’ Tree-Sit
July 18, 2019
Timothy M. Gill
Bernie Sanders, Anti-Imperialism and Venezuela
W. T. Whitney
Cuba and a New Generation of Leaders Respond to U.S. Anti-People War
FacebookTwitterRedditEmail